As a MNTA long, I’ll be content if annualized US Copaxone sales in May 2014 are still in the neighborhood of $3B. Based on the 3Q13 number ($798M) and the likelihood of another Copaxone price increase in January, the chances look pretty good.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”